Dialysis patients taking a particular intravenous vitamin D formulation have a significant survival advantage over patients taking an older and more commonly used form of vitamin D, according to a study published in the July 31, 2003, edition of the New England Journal of Medicine. Led by a Massachusetts General Hospital (MGH) physician, the three-year study found that patients receiving paricalcitol had a 16 percent greater chance of survival than did patients receiving calcitriol. The researchers stress that while this was a large-scale study of dialysis patients living throughout the United States, further studies are required before firm conclusions can be made.
"This is the first evidence that a specific form of vitamin D can change the high rate of mortality among dialysis patients," says Ravi Thadhani, MD, MPH, of the MGH Renal Unit, the paper's senior author. "If further research confirms our findings, this will be very important information for dialysis patients and their physicians."
Among the approximately 400,000 U.S. patients who receive dialysis for chronic kidney failure, the annual mortality rate is 20 percent. Several approaches have been tried to improve that statistic over the past decade, but few if any have been very successful. Cardiovascular disease is the primary cause of death among dialysis patients, and recently attention has been paid to the impact of hyperparathyroidism overactivity of the parathyroid gland on vascular disease.
Part of an imbalance in bone and mineral metabolism that results from kidney failure, hyperparathyroidism is usually treated with intravenous vitamin D therapy. However, treatment with vitamin D may exacerbate cardiovascular disease. Paricalcitol is a vitamin D analog that was approved by the U.S. Food and Drug Administration in 1998 to treat hyperparathyroidism associated with kidney failure. Because paricalcitol was known to be associated with more stable blood calcium andPage: 1 2 3 Related medicine news :1
Contact: Georgia Peirce
Massachusetts General Hospital
. Newer formulation of heparin improves outcomes for suspected heart attack patients2
. Newer rheumatoid arthritis drugs: Harmful on the liver?3
. Newer lung cancer treatments extend survival longer than traditional regimens4
. Newer form of gold standard drug helps kidney transplant patients do better in long term5
. Physicians Slow To Adopt Newer Drugs For Atrial Fibrillation6
. Not enough evidence that multivitamins prevent infections in the elderly7
. Folic acid and vitamin B12 decrease risk of hip fracture in stroke patients8
. Calcium and vitamin D most effective for treatment of Crohns-related bone loss9
. High doses of vitamin E supplements do more harm than good10
. Study shows high-dose vitamin E supplements may increase risk of dying11
. Center refutes finding that added sugars displace vitamins and minerals